Tumor Treating Fields Improve Pancreatic Cancer Quality of Life
A prespecified secondary analysis of the PANOVA-3 trial found better pain and quality-of-life outcomes with added tumor treating fields.
Updated on Nov. 16, 2026 in Cancer

Tumor treating fields combined with gemcitabine and nab-paclitaxel improved quality of life and pain outcomes compared with chemotherapy alone in patients with previously untreated, unresectable, locally advanced pancreatic adenocarcinoma. The findings come from a prespecified secondary analysis of the phase 3 PANOVA-3 trial, published in JAMA Network Open.
Why it matters
Prior PANOVA-3 results showed tumor treating fields improved overall survival, and this analysis adds evidence on how patients feel during treatment. Measured patient-reported outcomes such as pain and digestive symptoms may inform treatment decisions alongside survival data.
Median deterioration-free survival for pain was 10.1 months versus 7.4 months and for pancreatic pain 14.7 versus 10.2 months, with median time to opioid use at 9.3 versus 6.7 months in the mITT population. The analysis does not report whether these symptom gains persist beyond the 26-month follow-up.
The players
PANOVA-3 trial
PANOVA-3 is a phase 3 randomized trial that previously showed tumor treating fields improved overall survival in patients with unresectable pancreatic cancer.
JAMA Network Open
JAMA Network Open is an open-access, peer-reviewed medical journal published by the American Medical Association.
The details
Patients were randomly assigned to receive either tumor treating fields plus gemcitabine and nab-paclitaxel, or gemcitabine and nab-paclitaxel alone, with 285 and 286 patients respectively. In the treatment arm, digestive symptoms, pain and pancreatic pain improved from two months after treatment initiation, while global health status remained stable in both arms over 26 months of follow-up.
Timeline
Digestive symptoms, pain and pancreatic pain improved from two months after treatment initiation.
Quality-of-life outcomes were evaluated over a 26-month follow-up period.
The study was published online in JAMA Network Open on November 13, 2026.
Health Landscape
This analysis extends the PANOVA-3 trial, which previously reported an overall survival benefit for tumor treating fields, by adding patient-reported quality-of-life and pain outcomes. Together, the two reports widen the evidence base for a treatment that targets the aggressive pancreatic cancer population studied in that trial.
For patients with locally advanced pancreatic cancer, the analysis suggests that adding tumor treating fields to chemotherapy may reduce digestive symptoms and pain. Patients and clinicians may weigh these symptom outcomes alongside survival data when discussing treatment options.
The takeaway
Patients weighing pancreatic cancer treatment options may ask their oncology team how symptom and quality-of-life outcomes factor into the choice between chemotherapy alone and combined treatment. Survival and symptom benefits are both worth considering.
Further reading
Explore more Cancer research and treatment coverage for context on how pancreatic cancer therapies are evolving.
More information
Read the full JAMA Network Open study on TTFields quality of life for complete methods and results.
Source note: This article includes information reported by Cancer Therapy Advisor.







